SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive: Some of the factors implicated in poor response to CML therapy include low level of expression of molecular transporter hOCT1 and multidrug resistance gene (MDR1) polymorphisms [43]–[44].